

1632

COPY OF PAPERS
ORIGINALLY FILED



ATTORNEY'S DOCKET NO: C1040/7010(HCL/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 23 2002

Applicant: Heather L. Davis and Michael J. McCluskie
Serial No: 09/768,012
Conf. No: 9273
Filed: January 22, 2001
For: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING A TH
IMMUNE RESPONSE
Examiner: D. Nguyen
Art Unit: 1632

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on May 7, 2002.

Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

Transmitted herewith are the following documents:

- ☒ Response to Restriction Requirement
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,

Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
Federal Reserve Plaza, 600 Atlantic Avenue
Boston, MA 02210-2211
Attorney for Applicants

Docket No. C1040/7010(HCL/MAT)
Date: May 7, 2002
X05/09/02



COPY OF PAPERS
ORIGINALLY FILED

#14.
Dip
5/22/02

ATTORNEY'S DOCKET NO: C1040/7010(HCL/MAT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Heather L. Davis and Michael J. McCluskie
Serial No: 09/768,012
Conf. No: 9273
Filed: January 22, 2001
For: IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING A TH2
IMMUNE RESPONSE
Examiner: D. Nguyen
Art Unit: 1632

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on May 7, 2002.

Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents
Washington, D.C. 20231

Response to Restriction Requirement

Sir:

In response to the Restriction Requirement mailed from the United States Patent and Trademark Office on April 9, 2002, Applicants hereby request entry of the following election. This response is made within the one month deadline, and thus no fee is considered due.

Election

Applicants hereby elect Group I (claims 1-31, 52 and 100).

Applicants further elect

- a) an administration route that is mucosal administration with mouth as the targeted delivery site;
- b) a Th1 adjuvant that is QS21;
- c) a Th2 adjuvant that is a mucosal adjuvant;
- d) a Th2 adjuvant (mucosal adjuvant) that is bacterial toxins;
- e) a specially named formulation that is a liquid solution;
- f) a specifically named administration route that is oral;